Inhibition of triazolam clearance by macrolide antimicrobial agents: In vitro correlates and dynamic consequences

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 3, 1998, Pages 278-285

  Greenblatt, David J ^a   Von Moltke, Lisa L ^b   Harmatz, Jerold S ^b   Counihan, Molly ^b   Graf, Jennifer A ^b   Durol, Anna Liza B ^b   Mertzanis, Polyxane ^b   Duan, Su Xiang ^b   Wright, C Eugene ^b   Shader, Richard I ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; CYTOCHROME P450; ERYTHROMYCIN; MACROLIDE; TRIAZOLAM; TROLEANDOMYCIN;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG POTENCY; ELECTROENCEPHALOGRAPHY; HUMAN; HUMAN TISSUE; LIVER CLEARANCE; LIVER MICROSOME; MOOD; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECALL; SEDATION;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; AZITHROMYCIN; CLARITHROMYCIN; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DOUBLE-BLIND METHOD; ERYTHROMYCIN; HUMANS; HYPNOTICS AND SEDATIVES; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; TIME FACTORS; TRIAZOLAM; TROLEANDOMYCIN;

EID: 13144257695     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90176-X     Document Type: Article

References (27)

1. Henricsson S, Lindholm A, Aravoglou M. Cyclosporin metabolism in human liver microsomes and its inhibition by other drugs. Pharmacol Toxicol 1990;66:49-52.
2. Pichard L, Fabre I, Fabre G, Domergue J, Saint Aubert B, Mourad G, et al. Cyclosporin A drug interaction: screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990;18:595-606.
3. Petri P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992;23:106-31.
4. Silverman R. Mechanism-based enzyme inactivators. Methods Enzymol 1992;249:241-82.
5. Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Sugawara K, et al. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther 1996;59:514-9.
6. Warot D, Bergougnan L, Lamiable D, Berlin I, Bensimon G, Danjou P, et al. Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation. Eur J Clin Pharmacol 1987;32:389-93.
7. Olkkola K, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993;53:298-305.
8. Phillips JP, Antal EJ, Smith RB. A pharmacokinetic drug interaction between erythromycin and triazolam. J Clin Psychopharmacol 1986;6:297-9.
9. Yeates RA, Laufen H, Zimmermann T, Schumacher T. Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin, clarithromycin, and the azalide azithromycin. Int J Clin Pharmacol Ther 1997;35:577-9.
10. Mattila M, Vanakoski J, Idänpään-Heikkilä J. Azithromycin does not alter the effects of oral midazolam on human performance. Eur J Clin Pharmacol 1994;47:49-52.
11. Backman J, Olkkola K, Neuvonen P. Azithromycin does not increase plasma concentrations of oral midazolam. Int J Clin Pharmacol Ther 1995;33:356-9.
12. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996;276:370-9.
13. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989;36:89-96.
14. von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, et al. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 1996;36:783-91.
15. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994;268:1278-83.
16. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994;38:23-31.
17. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol 1998;38:112-21.
18. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998;38:106-11.
19. Greenblatt DJ, Harmatz JS, Gouthro TA, Locke J, Shader RI. Distinguishing a benzodiazepine agonist (triazolam) from a non-agonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies. Clin Pharmacol Ther 1994;56:100-11.
20. Greenblatt DJ, Harmatz JS, Shapiro L, Engelhardt N, Gouthro TA, Shader RI. Sensitivity to triazolam in the elderly. N Engl J Med 1991;324:1691-8.
21. Shader RI, Dreyfuss D, Gerrein JR, Harmatz JS, Allison SJ, Greenblatt DJ. Sedative effects and impaired learning and recall following single oral doses of lorazepam. Clin Pharmacol Ther 1986;39:526-9.
22. Greenblatt DJ, Harmatz JS. Kinetic-dynamic modeling in clinical psychopharmacology. J Clin Psychopharmacol 1993;13:231-4.
23. Laurijssens BE, Greenblatt DJ. Pharmacokinetic-pharmacodynamic relationships for benzodiazepines. Clin Pharmacokinet 1996;30:52-76.
24. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI. Metabolism of drugs by cytochrome P450 3A isoforms: implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995;29(suppl 1):33-43.
25. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI. In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 1998;55:113-22.
26. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-58.
27. Greenblatt DJ, von Moltke LL. Can in vitro models predict drug interactions in vivo? A review of methods, problems, and successes. In: Hori W, editor. Drug-drug interactions: analyzing in vitro-in vivo correlations. Southboro (MA): International Business Communications; 1997. p. 2.2.1-2.2.28.